Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy.

bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol 1999; 82: 511–516. 4 Salez F, Brichet A, Desurmont S, et al. Effect of itraconazole therapy in allergic bronchopulmonary aspergillosis. Chest 1999; 116: 1665–1668. 5 Montoya JG, Chaparro SV, Celis D, et al. Invasive aspergillosis in the setting of cardiac transplantation. Clin Infect Dis 2003; 37: 281–292. 6 Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46: 1401–1408. 7 Monforte V, Ussetti P, López R, et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 2009; 28: 170–175. 8 Laoudi Y, Paolini JB, Grimfeld A, et al. Nebulised corticosteroid and amphotericin B: an alternative treatment for ABPA? Eur Respir J 2008; 32: 908–909. 9 Proesmans M, Vermeulen F, Vreys M, et al. Use of nebulized amphotericin B in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Int J Pediatr 2010; 23: 376287. 10 Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068–1076.